Corona Remedies Limited
Promoters Dr. Kirtikumar Laxmidas Mehta · Niravkumar Kirtikumar Mehta · Ankur Kirtikumar Mehta
Against an issue price of ₹1,062. Split- and bonus-adjusted official closes — a past move, never a forecast.
Corona Remedies Limited raised ₹655 crore through a mainboard initial public offer.
The filing places it in Pharmaceuticals & Biotechnology and names three promoters: Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta and Ankur Kirtikumar Mehta.
The book was open from 8 December 2025 to 10 December 2025.
The issue was priced at ₹1,062 a share, from a band of ₹1,008 to ₹1,062.
The whole offer is an offer for sale — ₹656 crore paid to existing shareholders selling down, not to the company.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
The shares listed on 15 December 2025.
The last official close on file is ₹2,380 (5 November 2026), which is 124.1% above the issue price.
It now trades as CORONA, and its filed financials are on its company page.
Shares sold in the issue at ₹1,062 last closed at ₹2,379.8.
See CORONA’s filed financials and price history →Official exchange closes, restated for splits, bonuses and rights issues since listing. A record of past price movement, not a forecast.
No fresh issue — every share in this offer is being sold by existing shareholders, so the company itself raises nothing.
- Registrar
- Bigshare Services Pvt Limited
- Lead manager
- JM Financial Consultants Private Limited
- Bidding opens8 Dec 2025
- Bidding closes10 Dec 2025
- Basis of allotmentnot published
Not published in the exchange feeds we ingest — we do not estimate it.
- Listing15 Dec 2025
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We have not extracted an anchor allotment list for this issue.
- Anchor investors — first trancheSEBI ICDR 2018 Reg. 32(5)(b) — 50% of the anchor allocation, 30 days from allotment14 Jan 202650% of this tranche
- Anchor investors — second trancheSEBI ICDR 2018 Reg. 32(5)(a) — the remaining 50% of the anchor allocation, 90 days from allotment15 Mar 202650% of this tranche
- All other pre-issue capitalSEBI ICDR 2018 Reg. 17 — all other pre-issue capital, 6 months from allotment15 Jun 2026already free
- Promoters' minimum contributionSEBI ICDR 2018 Reg. 16(1)(a) — promoters' minimum contribution, 18 months from allotment15 Jun 2027whole tranche releases on this date
Computed from the SEBI ICDR 2018 lock-in rules, not disclosed by the issuer or the exchange. The regulation counts from the date of allotment, which no feed we ingest publishes, so these are counted from the listing date and fall at most two to three business days later than the true expiry.
The "Basis for Offer Price" chapter states the earnings the price was set against and the multiples it implies. We have not extracted it for this issue — several offer documents are served as .zip archives or as scanned pages with no text layer.
We have not extracted this section from the offer document for this issue yet. It is read from the abridged prospectus, and several offer documents are served as .zip archives or as scanned pages with no text layer.
We have not extracted this section from the offer document for this issue yet. It is read from the abridged prospectus, and several offer documents are served as .zip archives or as scanned pages with no text layer.
The offer document must name the listed companies the issuer considers comparable, and print their valuation figures beside its own. This is that list — the issuer’s choice of comparison, not ours.
| Company | P/E | P/B | RoNW | EPS | Income |
|---|---|---|---|---|---|
| Abbott India Limited | 45.2 | — | 33.4% | 665.62 | ₹64,092 cr |
| Alkem Laboratories Limited | 31.4 | — | 18.1% | 181.11 | ₹1,29,645 cr |
| Eris Lifesciences Limited | 61.8 | — | 12.2% | 25.85 | ₹28,936 cr |
| GlaxoSmithKline Pharmaceuticals Limited | 46.9 | — | 47.5% | 54.76 | ₹37,492 cr |
| J.B. Chemicals & Pharmaceuticals Limitednot in our universe | 42.6 | — | 19.2% | 42.45 | ₹39,180 cr |
| Mankind Pharma Limited | 45.8 | — | 13.9% | 49.28 | ₹1,22,074 cr |
| Pfizer Limited | 29.6 | — | 18.2% | 167.79 | ₹22,814 cr |
| Sanofi India Limited | 24.5 | — | 48.1% | 179.46 | ₹20,132 cr |
| Torrent Pharmaceuticals Limited | 65.9 | — | 25.2% | 56.47 | ₹1,15,161 cr |
The issuer's own figures as printed at the head of the same table — its claim about itself, on the same basis as its claims about the companies below.
Figures as PRINTED by the issuer in its own offer document. The comparison set is the issuer's choice, not ours.
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
JM Financial Consultants Private Limited 2024 – 2025 | 2 0 measurable | — | — | — | — |
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Bigshare Services Private Limited 2021 – 2026 | 219 22 measurable | +10.9% | 8 of 23 | 7 of 13 | 4 of 7 |
A count of what happened to the other issues each firm was named on, computed from exchange closes. Not a rating, not a ranking, and not a view on the firm.
- Prospectus· PDF · exchange archive11 Dec 2025
- Draft red herring prospectus (DRHP)· PDF · exchange archive30 Apr 2025
- Anchor investor allotment· ZIP · exchange archiveThis document is a scan with no text layer — readable by eye, not by machine.
- Financial ratios advertisement· ZIP · exchange archive
- In-principle approval (XBRL)· XML · exchange archive
- Listing filing (XBRL)· XML · exchange archive
Filed with SEBI and the exchanges by the issuer. These are the source for every figure on this page.
Compiled from NSE and SEBI offer documents and exchange feeds. A description of the issue and of the bids received — not investment advice, and not a view on whether to apply. No grey-market premium, no allotment lookup and no listing-gain estimate is published here.